Akrikhin company vacancies. History of the company Staraya Kupavna pharmaceutical plant
The company JOINT STOCK COMPANY "CHEMICO-PHARMACEUTICAL PLANT "AKRIKHIN" 5031013320 is registered at 142450, MOSCOW REGION, STARAYA KUPAVNA CITY, NOGINSKY DISTRICT, KIROVA STREET, 29. The organization was registered on 09.08.2002 The organization was issued an All-Russian State Registration number- 1025003911570. The organization is managed by PRESIDENT CHETVERIKOV DENIS VALERIEVICH. In accordance with registration documents the main activity is production medicines and materials used for medical purposes. To obtain more detailed information, you can go to the company’s card and check the reliability of the counterparty.
Interdistrict Inspectorate of the Federal tax service No. 23 in the Moscow region was registered on 08/09/2002 by AKRIKHIN JSC. Registration procedure for a State institution - Management Pension Fund RF No. 13 Noginsk district of the Moscow region was initiated on August 14, 2006. Registered with Branch No. 31 Government institution- Moscow regional branch of the Foundation social insurance Russian Federation the company JSC "AKRIKHIN" became 10/18/2008 00:00:00. Last entry in Unified State Register of Legal Entities, which is contained about this company: State registration changes made to the constituent documents of a legal entity related to changes in information about the legal entity contained in the Unified state register legal entities, based on the application.
"AKRIKHIN" Today it is one of the leading Russian pharmaceutical companies producing affordable, effective and high-quality medicines.
AKRIKHIN was founded in 1936. The company is among the top 10 largest local pharmaceutical manufacturers in terms of sales and production volume on the Russian pharmaceutical market.
The company's product portfolio includes more than 200 types of drugs (more than 100 brands) in the main pharmacotherapeutic areas: cardiology, neurology, dermatology, gynecology, pediatrics, ophthalmology, urology. These are drugs like own production"AKRIKHINA", and displayed on Russian market in partnership with other companies.
"AKRIKHIN" produces a wide range of socially significant, contributing to the development Russian system healthcare. The company is one of the largest Russian manufacturers drugs included in the List of Vital and Essential Medicines (VED), as well as drugs for the treatment of tuberculosis and diabetes.
Production complex "AKRIKHINA" is located 20 km from Moscow. The company's production includes workshops for the production of medicines of almost all forms: tablets, capsules, liniments, ointments, creams, syrups, gels, suppositories, etc. The company's annual production volume is more than 50 million packages. are produced on foreign equipment from high-quality raw materials based on latest technologies. The modern warehouse complex "AKRIKHINA" has more than 8 thousand pallet spaces that ensure proper storage of medicines.
Since 2007, AKRIKHIN's strategic partner on the Russian pharmaceutical market has been Polpharma. Strategic cooperation between AKRIKHIN and Polpharma includes:
- unified product portfolio,
- transfer production technologies and cooperation in research and development,
- access to international management standards and technologies, employee training, exchange programs.
In 2011, Polpharma strengthened and expanded the partnership by acquiring a majority stake in AKRIKHIN.
Part production complex"AKRIKHINA" includes:
- 2 production facilities for the production of finished dosage forms:
- solid finished dosage forms,
- soft and liquid finished dosage forms;
- Quality Control Center;
- R&D laboratory;
- Stock finished products;
- Bonded warehouse;
- Warehouse of raw materials and supplies.
Each stage of drug creation is accompanied by quality control. This is ensured by the company's quality assurance system. AKRIKHIN regularly successfully passes audits of foreign partners and regulatory authorities for compliance of the quality assurance system and quality management system with ISO standards and rules.
In 2010, AKRIKHIN began implementing an investment program for the period 2010-2016. for the modernization and development of the production complex with a total investment of more than 40 million dollars. As a result of the implementation of the investment program, the company will significantly increase the volume of output and will finally complete the transition of the entire production complex to compliance with the requirements international standards quality
> Akrikhin, JSC (Moscow)
This information cannot be used for self-medication!
Consultation with a specialist is required!
The full name of the company is Akrikhin Chemical and Pharmaceutical Plant. Is Russian company, is engaged in the production of a variety of dosage forms: tablets, syrups, ointments, creams and capsules. Most of manufactured products are focused on socially significant therapeutic areas of medicine. These include endocrinology, cardiology, neurology, phthisiology, and gynecology.
In Russia, Akrikhin OJSC was officially registered in 2003, although the history of production begins in 1936, when the manufacturer produced a batch of the antimalarial drug Akrikhin, which later gave the company its name.
Currently, the actual owner of Akrikhin OJSC is the Hungarian pharmaceutical giant Gedeon Richter, which owns more than 80% of the company's shares. Another co-owner is the Polish pharmaceutical company Polpharma. Foreign investments allowed the chemical and pharmaceutical plant to enter the top ten Russian drug manufacturers. About 40% of all manufactured drugs are included in the list of vital means
Akrikhin company produces the following drugs:
- gel Azelik to combat acne;
- creams and ointments for the treatment of atopic dermatitis and complicated dermatoses – Akriderm-Ghenta, Akriderm-GK;
- pills Acridilol And Acripamide for the treatment of coronary heart disease;
- Effervescent tablets for treating hangovers – Alca Prim;
- drops for children Bobotik from bloating;
- ointment and tablets Acyclovir-Acri for the treatment of herpes infection;
- painkiller Bystrumgel;
- means for the treatment of varicose veins - Venolife;
- drugs for the treatment of diabetes mellitus – Glidiab And Glymecombe;
- dietary supplement Zhuravit;
- anti-tuberculosis drugs - Isocomb, Pask-Acri, Pyrazinamide-Acri, Rifapex;
- remedy for the treatment of allergic reactions - Clarotadine tablets and syrup;
- antimicrobial agent Clindacin for the treatment of bacterial vaginosis;
- antidiarrheal drug Loperamide-Acree;
- medicinal shampoo Mycozoral with antifungal effect;
- eubiotics Normobakt, Normobakt Junior for the treatment of dysbacteriosis;
- Nozzle– patch for inhalation;
- ophthalmic biological additive – SuperOptic;
- Thrombopol– a blood thinner;
- drugs for the treatment of diseases of the musculoskeletal system – Febrofid-gel, Diclofenac;
- antihypertensive pills Enalapril-Acri;
- L-Thyroxine-Acri– a drug for the treatment of thyroid diseases.
In the 30s of the 20th century, the incidence of malaria in Russia exceeded 9 million people. The drug Akrikhin, which gave the name to the enterprise, saved the country from the outbreak of the epidemic. On October 19, 1936, the first industrial batch of Akrikhin weighing 22 kg was received. During the first years of the Chemical Plant's existence, 6 production buildings were built and put into operation, capacity was increased tens of times, and by 1939 AKRIKHIN became the largest chemical and pharmaceutical enterprise producing the most important medicines for the country's population: Akrikhin, Streptocide white and red, Anesthetic ether, sulfidine.
1940s:
everything for the front!
The words “Everything for the front, everything for Victory!” became the goal and meaning of life of the plant during the war years. On the fronts of the Great Patriotic War More than 1,200 Akrikhanovites fought. 362 people did not return from the front.
In 1941, in a record 72 hours (!), Akrihinovites launched the production of bottles with a combustible mixture - the famous “KS” (Molotov cocktail). The production was extremely dangerous, the only salvation from burns was a ditch with water, into which you had to jump if the COP got on your clothes or skin. Thanks to this ditch at the entrance to the workshop, none of the workers were seriously injured.
In the post-war years, a course was taken to restore and increase the plant's capacity. By 1948, pharmaceutical production had reached pre-war levels.
1950s:
we will implement the plan
and overfulfill
In the 50s, AKRIKHIN increased its production capacity at an unprecedented pace, mastering about 80 items new products(both substances and finished dosage forms) and becomes the flagship of the Soviet chemical and pharmaceutical industry.
During this period, AKRIKHIN launched the first antibiotic, syntomycin, and also became the first and only manufacturer of synthetic sex hormones in the country. Since 1951, AKRIKHIN began producing substances of anti-tuberculosis drugs, and since 1953, ready-made forms in the form of tablets. To this day, AKRIKHIN is one of the country's largest manufacturers of drugs for the treatment of tuberculosis.
1960s:
course for large-scale
construction
By 1963, the domestic pharmaceutical industry satisfied the demand for medicines only (!) by 77%, which in those years was considered insufficient. AKRIKHIN has set a course for large-scale construction and reconstruction of production. In the 60s, 6 new production buildings, a laboratory, two plant management buildings were built, and a large-scale reconstruction of seven existing buildings took place. All this was built under the conditions of a working plant and the implementation of strict production plans.
In the year of its 30th anniversary, AKRIKHIN received a high government award - the Order of the Red Banner of Labor
1970s:
unprecedented
production growth
By 1973, construction, which began in the 60s, was completed, and the workshops were gaining production capacity. The growth rate indicators were expressed in convincing figures - 75.5% in 1975 compared to the 1970 level, 65% in 1980 compared to the 1975 level.
AKRIKHIN provided 24% of the total production of pharmaceutical substances in the USSR and supplied substances to 44 enterprises in the country.
The 70s became the most active period for the export of medicines from the AKRIKHIN plant. During the Soviet period, in the list of product exporting states
54 countries of the world were listed, i.e. ready medicines In some cases, global pharmaceutical companies were produced on the basis of active substances produced by the Soviet AKRIKHIN plant. AKRIKHIN confidently holds its position as the flagship of the Soviet pharmaceutical industry.
1980s:
new economic
conditions
In the 80s, the growth rate of production at the AKRIKHIN plant remained high: 36.3% in 1985 compared to the 1980 level and 33.3% in 1990 compared to the 1985 level.
In 1988, a new milestone began in the history of AKRIKHIN - work under conditions of complete self-financing and self-financing. Due to the rise in prices for energy resources and raw materials (more than 300 types were used!), the production of substances became unprofitable. "AKRIKHIN" was looking for its development path in new economic conditions. An important step in this direction was the signing in 1988 of an agreement with the company KRKA (Slovenia) on the launch of the first cooperation project for the production of finished dosage forms. This project was a turning point in terms of the introduction of new technologies and the quality of finished products and predetermined further development companies.
1990s:
from survival
to a strategy for success
In the early 90s, the plant's management decided to redirect from the unprofitable synthesis of substances (more than 75% of production) to the production of finished medicines.
In 1990, AKRIKHIN was the first enterprise in the industry to enter into a licensing agreement with Bristol-Myers Squibb (BMS) for the production of cardiovascular drugs. As a result, in 1992, at the existing production site of AKRIKHIN, together with BMS, the country's first industrial workshop was built, fully complying with GMP standards. The 20-year collaboration between AKRIKHIN and Bristol-Myers Squibb remains the longest-term licensing project in the history of the Russian pharmaceutical industry. This project became a turning point in terms of the introduction of new technologies and predetermined the future fate of AKRIKHIN as a manufacturer of finished drugs.
In 1995, AKRIKHIN was the first among industry enterprises to launch an import substitution program - the development, registration and production of drugs not produced in Russia. It includes 15 drugs most in demand in healthcare. At the same time, it was decided to produce drugs under the INN with the prefix Acri.
In 1996, with the release of the first antidiabetic drug, AKRIKHIN began to develop one of the most important areas- diabetes. In total, since this time the company has launched 6 oral hypoglycemic drugs on the market, all of them are own developments companies.
The transition to new economic tracks was completed with the creation of the center in 1996 marketing research and began producing drugs under its own trade names.
2000s:
Sustainable growth
The year 2007 marked the beginning strategic partnership with the largest Polish pharmaceutical company Polpharma. The partnership involves close cooperation between companies in the development, production, promotion and distribution of medicines.
